SecBot SecBot
144 ·Filed Nov 10, 2026

CORT

CORCEPT THERAPEUTICS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed6d 7h ago SEC0001950047-26-010947
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale is small and routine for a director; no material impact expected. Monitor for any larger insider sales or changes in insider filing patterns ahead of the next earnings report.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$74.53
T+0 close · Nov 10, 2026 · via day close
Latest settled
−1.10%
T+1 · $73.71
Vs SPY
−0.75%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $74.53entry
  2. T+1 · 5d ago −1.10%α −0.75% · $73.71
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Daniel Swisher Jr. filed a Form 144 notice of intent to sell 1,500 shares of Corcept Therapeutics common stock, with an estimated aggregate market value of $112,537.50. The shares were acquired through exercise of stock options on the same day. This is a small, routine sale by a director and represents a negligible fraction of the company's $8.0B market cap.

Key Facts

  • Insider: Daniel Swisher Jr., Director
  • Shares to be sold: 1,500 shares of common stock
  • Estimated value: $112,537.50
  • Acquisition: shares acquired via exercise of stock options on 2026-11-10
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  • Proposed sale date: 2026-11-10
  • Market cap of CORT: $8.0B

Financial Impact

Sale of 1,500 shares valued at ~$112.5K, representing less than 0.002% of market cap

dilution

Risk Factors

  • Form 144 is an intent to sell; the actual sale may not occur
  • No additional context on the insider's total holdings is provided

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010947
Document: 0001950047-26-010947-index.html0001950047-26-010947
Document: 0001950047-26-010947.txt0001950047-26-010947

Track record

36 reports on CORT

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
  2. Nov 10, 20266d ago 144 Neutral 2/10 Viewing Entry $74.53 Now $69.22 −7.12% settles Dec 10
  3. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
  5. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
  7. Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
  8. Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
  9. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
  10. Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 9h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026